North Dakota Senators vote to block insulin price cap
Hoeven, Cramer say insulin costs can be cut more efficiently without sweeping legislation
BY CAMMIE WRIGHT
cammie@nordaknorth.com
The US Senate voted against a price cap on insulin for private insurers during its reconciliation of the sweeping Inflation Reduction
Act. Democrats had tried to preserve the provision to cap insulin costs at $35 per month for private insurers, but that vote failed 57-43, with seven Republicans voting to keep the insulin cost cap in the bill, three short of what was needed. Both North Dakota Senators John Hoeven and Kevin Cramer voted against the cap. The cost of insulin in the United States is higher than in 32 comparable, high-income nations combined. According to a study from the Mayo Clinic, the average American insulin user spent $3,490 on insulin in 2018 compared with
$725 among Canadians.
